In Ukraine, the top sold Paracetamol is the medicine produced by Darnitsa, pharmaceutical company. Dmytro Shymkiv, Head of the Board of Directors of Darnitsa, shared the research results of Proxima Research. According to the results of analysis performed by it, for three quarters of 2021, the share of Darnitsa-produced Paracetamol in the mono-preparations market was more than 71% in real terms, and 72.4% in monetary terms. Thus, Paracetamol-Darnitsa has become a leader among its competitors.
This is also evidenced by the results of a sociological survey conducted by Darnitsa together with the Gradus company. The target audience of the survey were consumers aged 18 to 60, of whom 72% said they regularly bought Paracetamol-Darnitsa at the chemist. 70% of the respondents also reported that they were willing to recommend this medicine to their friends, and 40% associate Paracetamol as such with Darnitsa, pharmaceutical company.
Dmytro Shymkiv emphasized that in order to provide the population with antiviral and antipyretic medicines due to the coronavirus pandemic last year, Darnitsa changed its industrial scheme. In particular, it launched additional production of Immustat began, and a large batch of Paracetamol was additionally produced.
Darnitsa, pharmaceutical company, was founded in 1930. Since 1998, it has been the leader in Ukraine in terms of the volume of production of medicines in physical terms. The company's mission is to help healthcare professionals and patients improve their quality of life through science, innovation, and accessibility to everyone. The company's portfolio includes 210 brands of medicines. The products of Darnitsa are exported to 16 countries of the world. The beneficiaries of the company are the Zahorii family. The Head of the Board of Directors is Dmytro Shymkiv.